Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMC vs Long-acting ACT for Malaria Prevention in Ghana
NCT01651416Phase 4Completed
- Sponsor
- Centre for Global Health Research
- Start
- Jul 2012
- Primary completion
- Dec 2012
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dihydroartemisinin + piperaquine and sulfadoxine + pyrimethamine + amodiaquine in malaria (3 arms), sponsored by Centre for Global Health Research. Primary endpoint: Incidence of malaria cases at 12 months. Started Jul 2012; status: completed.
02
Drugs
dihydroartemisinin + piperaquinesulfadoxine + pyrimethamine + amodiaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT01651416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01651416.